tetano
Editor, Senior Moderator
Immun Inflamm Dis
. 2024 Apr;12(4):e1232.
doi: 10.1002/iid3.1232. Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2 in the elderly: A single-center large observational study
Can Chen[SUP] 1 [/SUP], Ranyi Li[SUP] 1 [/SUP], Shuliang Xing[SUP] 2 [/SUP], Lei Cao[SUP] 3 [/SUP], Yue Qu[SUP] 4 [/SUP], Qianzhou Lv[SUP] 1 [/SUP], Xiaoyu Li[SUP] 1 [/SUP], Zhangzhang Chen[SUP] 1 [/SUP]
Affiliations
Background: Since coronavirus 2019 (COVID-19) swept the world, a variety of novel therapeutic and prevention strategies have been developed, among which nirmatrelvir-ritonavir is highly recommended. We intended to assess the effectiveness and safety of nirmatrelvir-ritonavir in the elderly mild-to-moderate COVID-19 population caused by the omicron BA.2.2 variant in real-world settings.
Methods: An observational study was conducted retrospectively to review the outcomes of mild-to-moderate COVID-19 patients admitted between April 26 and June 30, 2022. Patients' baseline characteristics were collected and assessed. Participants in the intervention group were administered nirmatrelvir-ritonavir in addition to standard care, whereas those in the control group only received standard care. The primary outcome was the duration between the initial positive reverse-transcription polymerase chain reaction (RT-PCR) test and the subsequent conversion to a negative result.
Results: The analysis included 324 patients who were administered nirmatrelvir-ritonavir and an equal number of control patients. The patient characteristics in both groups were evenly matched. The average duration from the initial positive RT-PCR to negative conversion was similar in both groups (16.2 ± 5.0 vs. 16.1 ± 6.3 days, p = .83). Control patients exhibited slower conversion in comparison to patients who received nirmatrelvir-ritonavir treatment within 10 days of symptom onset.
Conclusions: These findings suggest that administering nirmatrelvir-ritonavir within 10 days of symptom onset could potentially reduce the time it takes for SARS-CoV-2-infected patients to negative RT-PCR results, thereby expanding the current usage guidelines for nirmatrelvir-ritonavir.
Keywords: COVID‐19; nirmatrelvir–ritonavir; observational study.
. 2024 Apr;12(4):e1232.
doi: 10.1002/iid3.1232. Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2 in the elderly: A single-center large observational study
Can Chen[SUP] 1 [/SUP], Ranyi Li[SUP] 1 [/SUP], Shuliang Xing[SUP] 2 [/SUP], Lei Cao[SUP] 3 [/SUP], Yue Qu[SUP] 4 [/SUP], Qianzhou Lv[SUP] 1 [/SUP], Xiaoyu Li[SUP] 1 [/SUP], Zhangzhang Chen[SUP] 1 [/SUP]
Affiliations
- PMID: 38578027
- PMCID: PMC10996376
- DOI: 10.1002/iid3.1232
Background: Since coronavirus 2019 (COVID-19) swept the world, a variety of novel therapeutic and prevention strategies have been developed, among which nirmatrelvir-ritonavir is highly recommended. We intended to assess the effectiveness and safety of nirmatrelvir-ritonavir in the elderly mild-to-moderate COVID-19 population caused by the omicron BA.2.2 variant in real-world settings.
Methods: An observational study was conducted retrospectively to review the outcomes of mild-to-moderate COVID-19 patients admitted between April 26 and June 30, 2022. Patients' baseline characteristics were collected and assessed. Participants in the intervention group were administered nirmatrelvir-ritonavir in addition to standard care, whereas those in the control group only received standard care. The primary outcome was the duration between the initial positive reverse-transcription polymerase chain reaction (RT-PCR) test and the subsequent conversion to a negative result.
Results: The analysis included 324 patients who were administered nirmatrelvir-ritonavir and an equal number of control patients. The patient characteristics in both groups were evenly matched. The average duration from the initial positive RT-PCR to negative conversion was similar in both groups (16.2 ± 5.0 vs. 16.1 ± 6.3 days, p = .83). Control patients exhibited slower conversion in comparison to patients who received nirmatrelvir-ritonavir treatment within 10 days of symptom onset.
Conclusions: These findings suggest that administering nirmatrelvir-ritonavir within 10 days of symptom onset could potentially reduce the time it takes for SARS-CoV-2-infected patients to negative RT-PCR results, thereby expanding the current usage guidelines for nirmatrelvir-ritonavir.
Keywords: COVID‐19; nirmatrelvir–ritonavir; observational study.